MediWound Ltd.
MediWound Ltd. is an Israel-based biopharmaceutical company focused on enzymatic, non-surgical therapies for tissue repair and regeneration. Its portfolio centers on products for burn care, wound care, and related tissue restoration applications, with commercialization across selected global markets through direct sales and distributor channels.
Liiketoiminta
Osuus liikevaihdostaApproved and marketed treatment for eschar removal in severe thermal burns.
Development-stage and emerging products aimed at wound management and repair.
Underlying enzymatic technology used to create new biotherapeutic candidates.
Asiakkaat
MediWound sells primarily to burn centers, hospitals, and specialist clinicians that treat deep thermal burns and complex wounds. Its commercial model also relies on distributors and local partners in international markets that help secure market access and regulatory approvals. Research, procurement, and treatment decisions are driven by clinical outcomes, ease of use, and the ability to replace more invasive surgical procedures.
Buy NexoBrid for treatment of severe burns requiring eschar removal.
Use the product in acute care pathways for thermal burn management.
Handle commercialization and market access in selected regions.
Adopt therapies that may reduce invasive surgery and support standardized care.
Strategia
MediWound’s strategy is built around its enzymatic technology platform and expanding it into multiple biotherapeutic indications beyond the initial burn-care franchise. The company is also focused on global commercialization of NexoBrid while advancing next-generation programs such as EscharEx, using partnerships and regulatory milestones to expand addressable markets. This approach seeks to combine a marketed product with a pipeline that can broaden the company’s long-term commercial base.
A marketed product creates commercial traction, physician familiarity, and recurring market access infrastructure.
Pipeline expansion reduces dependence on a single product and broadens the clinical and commercial opportunity set.
Local approvals and distributor relationships determine how quickly the company can reach new markets.
Maantiede
MediWound is headquartered and operates from Yavne, Israel, while its commercial footprint extends into the European Union, the United Kingdom, Israel, and other international markets. The company uses direct commercialization in some markets and distributor-led channels in Asia Pacific, EMEA, CEE, and LATAM, which broadens reach but increases dependence on local regulatory and partner execution. Its geography matters because market access, reimbursement, and approval timing vary significantly by country.
Riskit
MediWound depends on continued regulatory approvals, market access, and commercial adoption of a small number of products, which makes execution risk important. As a development-stage biopharmaceutical company with a marketed product and pipeline candidates, it also faces clinical, reimbursement, manufacturing, and partner-channel risks typical of specialty biotech businesses. Funding needs, government support assumptions, and foreign market dependence can materially affect operating flexibility.
- Product concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A large share of commercial activity depends on NexoBrid, so any slower uptake or disruption can materially affect the business.
Kohdistuu: NexoBrid commercialization
- Regulatory and approval delaysVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company needs approvals and authorizations across multiple jurisdictions before expanding sales.
Kohdistuu: EscharEx and international markets
- Manufacturing and quality controlVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biopharmaceutical products require consistent production, validation, and supply chain reliability.
Kohdistuu: Commercial product supply
- Partner and distributor dependenceVaikutus: KeskitasoTodennäköisyys: Korkea
Local distributors are responsible for market access in several territories, so execution quality affects adoption and timing.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätCommercial product sales may be recognized differently across direct and distributor channels depending on delivery and control transfer.
Vaikutus: Affects quarterly revenue timing and comparability.
Biologic and specialty therapeutic inventory requires careful net realizable value assessment.
Vaikutus: Can affect cost of sales and write-down risk.
Option and RSU grants are part of employee compensation and are expensed over vesting periods.
Vaikutus: Affects operating expense and adjusted EBITDA reconciliation.
Product and development-related intangibles must be assessed for impairment as commercialization evolves.
Vaikutus: Can create non-cash charges if expected benefits weaken.
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Vericel Corp
VCEL · Biological Products, (No Diagnostic Substances)
Vericel Corp is a U.S.-based biopharmaceutical company focused on advanced therapies for cartilage repair and severe burn care.
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Turn Therapeutics Inc.
TTRX · Pharmaceutical Preparations
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Medicus Pharma Ltd.
MDCXW · Pharmaceutical Preparations
Päivitetty: 28.9.2026